EMCORE Corporation (Nasdaq:EMKR), a leading provider of compound semiconductor-based components and subsystems for the fiber optic and solar power markets, reported that it has entered into an OEM agreement with Lake Shore Cryotronics, Inc. to supply an OEM version of the PB7200 Portable Frequency Domain Terahertz (THz) Spectrometer Potential clients are much more thrilled in watching something, be it a presentation on how a material is put to use or an online video demonstration on a company's history, rather than reading something Crown Equity Holdings Inc., (CRWE) recenly launched CRWE Tube, www.crwetube.com, a video sharing site that allows billions of people around the world to upload, watch and share original videos. Restricting your marketing to just written text vastly limits your audience; video marketing should be seen as another mode of online communication to reach potential customers. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. CRWEs advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. More about CRWE at www.crownequityholdings.com. QLT Inc. (Nasdaq:QLTI) reported that it has completed the sale of the Company's Visudyne(r) business to Valeant Pharmaceuticals International, Inc. Under the terms of the agreement with Valeant, QLT received a payment of 112.5 million at closing and is eligible to receive additional amounts in contingent payments. 50 million of the initial purchase price is for the right to receive royalties on Visudyne sales outside of the United States under a license agreement with Novartis Pharma AG and the right to supply Visudyne to Novartis for sales outside of the United States, and 62.5 million of the initial purchase price is for the rights and assets of the Visudyne business in the United States. QLT is eligible to receive up to 5 million in contingent payments relating to the development of its laser program in the United States, up to 15 million in contingent payments relating to the Novartis non-U.S. royalties and a royalty on net sales of new indications for Visudyne, if any should be approved. Myriad Genetics, Inc. (Nasdaq:MYGN) reported that Noridian, the Medicare Administrator for Utah, has notified Myriad of its intent to add the Company's prostate-prognostic test, Prolaris(r), to its next draft Non-Covered Service LCD (local coverage determination). Noridian will solicit public and provider comment on the Prolaris test before making a final decision. THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: CRWENewswire.co.uk publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://CRWENewswire.co.uk/disclaimer)
